Presentations from Top Biopharma
Hear more than 30 presentations from top biopharma companies.
Preview the presentations below:
AbbVie
Identifying mAb Sequence and Structure Features for Developability Assessment
Christopher Negron, PhD, Principal Research Scientist, AbbVie, Inc.
Amgen
Assessing New and Sensitive Mass Spectrometry-Based Techniques to Rapidly Characterize Protein Therapeutics
Dhanashri Bagal, Principal Scientist, Discovery Attribute Sciences, Amgen, Inc.
Discovery of a Bispecific GIPR Antagonist Antibody and GLP-1 Peptide Conjugate (AMG 133) for the Treatment of Obesity
Yuan Cheng, PhD, Senior Principal Scientist, Therapeutic Discovery, Amgen, Inc.
Attenuating CD3 Affinity in a PSMAxCD3 Bispecific Antibody Enables Killing of Prostate Tumor Cells with Reduced Cytokine Release
Pranjali Dalvi, PhD, Senior Scientist, Amgen
On-Target Toxicity Associated with an Anti-CD70 Bispecific T Cell Engager Molecule in Cynomolgus Monkeys
Tod Harper, PhD, DABT Principal Scientist, Translational Safety, Amgen, Inc.
Advances in Multi-Specific Antibody Purification
John K. Kawooya, PhD, Director, Biologics Optimization and Therapeutic Discovery, Amgen, Inc.
Immune Repertoire Characterization from the Peripheral Blood of Mice
Karyn McFadden, PhD, Senior Scientist, Amgen, Inc.
Reimagining Protein Production Workflows to Enable Next-Generation Biologics?
Daniel Yoo, Principal Scientist, Therapeutic Discovery, Amgen, Inc.
AstraZeneca
Developability Assessment of Engineered Monoclonal Antibody Variants with a Complex Self-Association Behavior Using Complementary Analytical and in silico Tools
Neil Mody, PhD, Associate Director, AstraZeneca
Eli Lilly
Machine Learning to Predict Pharmaceutical Properties of Candidate Biotherapeutics
Qing Chai, PhD, Research Advisor, BioTechnology Discovery Research, Eli Lilly & Co.
The Influence of Configuration on Bispecific Antibody Physiochemical Properties, Pharmacokinetics, and Disposition
Amita Datta-Mannan, PhD, Senior Research Scientist, Drug Disposition Development, Eli Lilly & Co.
Characterization of Protein and Peptide Formulations
Shreya Madugula, Senior Engineer, Formulations, Eli Lilly & Co.
Genentech
Near-Term Vision for Applications of Machine Learning in Biopharmaceutical R&D
Tommaso Biancalani, PhD, Director and Senior Scientist, AI/ML, Genentech, Inc.
Employing High Sensitivity Nano-LCMS Methods for AAV Capsid Protein Analysis
Lance J. Cadang, Senior Research Associate, Protein Analytical Chemistry, Genentech, Inc
An Integrated Approach for Assessing Immunogenicity Risk of Biotherapeutics
Sivan Cohen, PhD, Scientist, Genentech
A Mechanistic Understanding of Monoclonal Antibody Interfacial Protection by Hydrolytically Degraded Polysorbate 20 and 80 under IV Bag Conditions
Aadithya Kannan, Scientist, Genetech
Characterization and Disruption of Ultra-Low Affinity HCP-mAb Interactions
Shrenik Mehta, PhD, Technical Development Scientist, Pharmaceutical Development Department, Genentech, Inc.
Online Multi-Dimensional LC/MS: The Next-Generation PAT Tool for Real-Time Monitoring of Antibody Quality Attributes in Biopharmaceutical Processes
Cinzia Stella, PhD, Senior Scientist, Tech Development, Genentech, Inc.
Development of an SPR-Based Binding Assay for Characterization of Anti-CD20 Antibodies to CD20 Expressed on Extracellular Vesicles
Xiangdan Wang, PhD, Principal Scientist, BioAnalytical Sciences, Genentech, Inc.
GlaxoSmithKline
Implementation of a Fully Automated Walk-Up Residual DNA qPCR Workflow
Michele Shannon, Investigator, GlaxoSmithKline
Janssen
Challenges and Opportunities in Cell Therapy Drug Product Development
Bharathi Vellalore, PhD, Senior Scientist, Biotherapeutics Drug Product Development, JanssenMerck
Coupling High-Density Data and High-Throughput Small-Scale Screening to Optimize DNA Construct Screening
Noel Byrne, Associate Principal Scientist, Structural Protein Sciences, Merck & Co., Inc.
Cell Line Development to Mitigate Development Risks of a Complex Protein
Ren Liu, PhD, Principal Scientist, Discovery Interface, Merck & Co., Inc.
Utilizing a Streamlined Automated Workflow to QC Baculovirus Expression
Andrea Partridge, PhD, Senior Scientist, Computational Structural Chemistry, Merck & Co., Inc.
Novo Nordisk A/S
LabDroid: A Highly Automated Variant Characterization Platform
Christoph Kalthoff, PhD, Director, LabDroid, Novo Nordisk A/S
Pfizer
Challenges and Opportunities Supporting Early-Stage Drug Discovery Projects
Oleg Brodsky, Senior Principal Scientist, Structural Biology & Protein Sciences, Pfizer Inc.
One Size Does Not Fit All: Navigating the Multi-Dimensional Space to Optimize T Cell Engaging Protein Therapeutics
Fan Yang, PhD, Senior Principal Scientist, Protein Engineering, Pfizer Inc.
Regeneron
Bispecific ADCs: Modulating Intracellular Trafficking to Improve Efficacy
Julian Andreev, PhD, Research Fellow, Oncology & Angiogenesis, Regeneron Pharmaceuticals, Inc.
Roche
From Dual Targeting Fabs to Tri- and Tetravalent IgGs
Janina Speck, PhD, Science and People Lead, LMR Discovery, Roche, Germany
Sanofi
Mass Spectrometry Applications in Cell & Gene Therapy
Jill Bradley-Graham, PhD, Scientist, BioAnalytics Characterization, Sanofi Genzyme
In vivo Reprogramming of CAR T Cells Using Targeted LNPs
Viktor Lemgart, Research Fellow, Tidal Therapeutics a Sanofi Company
NGS-Based Antibody Discovery from Phage Libraries Enables Deeper Repertoire Mining of Antigen-Specific Antibodies
Ankit Mahendra, PhD, Principal Scientist, Antibody Platform, Large Molecule Research, Sanofi USA
Size Characterization of Vaccine Antigens: Ensemble v/s Single Particle Analysis Approach
Rahul Misra, PhD, Scientist, Biophysics and Process Analytical Technology, Sanofi
Formulating Biologics Products at Low pH: Real-World Formulation Considerations, Processing Risks, and Mitigation Strategies
Sanket Patke, PhD, Associate Director, Sanofi